OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
MAGLE$3.5658

Magle Chemoswed Holding AB

PharmaceuticalsVerified

Magle Chemoswed Holding AB has a market price of 3.56 SEK, with a market capitalization of 105,016,831.6 SEK, and a price-to-book ratio of 0.27, indicating a significant discount to its book value. The company's liquidity position is characterized by a current ratio of 1.37, suggesting it has sufficient short-term assets to cover its liabilities, but its cash and equivalents of 13,593,000 SEK are insufficient to cover its long-term debt of 346,187,000 SEK, resulting in a negative net cash position. Profitability metrics show a return on equity of -40.39% and a return on assets of -17.55%, both significantly below industry norms, indicating poor capital efficiency and operational performance. The company reported a net loss of 159,884,000 SEK and an operating loss of 126,963,000 SEK, with a gross profit of 232,427,000 SEK, suggesting high operating costs relative to revenue. The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification, which increases exposure to regional economic or regulatory risks. The lack of segmental or geographic breakdown in the financial data limits the ability to assess diversification benefits or concentration risks. Looking ahead, the company is expected to see a revenue increase to 345,000,000 SEK, a 21.96% year-over-year growth, according to analyst estimates. However, the operating cash flow of -31,930,000 SEK and free cash flow of -72,227,000 SEK indicate ongoing cash burn, which could constrain growth initiatives or necessitate external financing. The company faces liquidity and dilution risks, with a debt-to-equity ratio of 0.87 and a negative net cash position. Analysts have assigned a medium liquidity risk rating, and the company's dilution risk is currently low, with no near-term pressure expected. However, the negative operating cash flow and free cash flow suggest potential future dilution if the company requires additional capital. Recent financial filings and transcripts indicate that the company is in a development phase, with a focus on product innovation and market expansion. The company's current financial performance, including a net loss and negative cash flows, suggests that it is not yet generating sustainable profits and may require continued investment to achieve long-term growth.

30-day price · MAGLE(missing data)
No daily-bar history available from current data sources. Alternate source pending.
Profile
CompanyMagle Chemoswed Holding AB
TickerMAGLE.ST
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryPharmaceuticals
AI analysis

Business. Magle Chemoswed Holding AB operates in the pharmaceuticals industry, focusing on the development and production of pharmaceutical products and related services.

Classification. The company is classified under the Healthcare economic sector, within the Pharmaceuticals & Medical Research business sector, with a classification confidence of 0.92.

Magle Chemoswed Holding AB has a market price of 3.56 SEK, with a market capitalization of 105,016,831.6 SEK, and a price-to-book ratio of 0.27, indicating a significant discount to its book value. The company's liquidity position is characterized by a current ratio of 1.37, suggesting it has sufficient short-term assets to cover its liabilities, but its cash and equivalents of 13,593,000 SEK are insufficient to cover its long-term debt of 346,187,000 SEK, resulting in a negative net cash position. Profitability metrics show a return on equity of -40.39% and a return on assets of -17.55%, both significantly below industry norms, indicating poor capital efficiency and operational performance. The company reported a net loss of 159,884,000 SEK and an operating loss of 126,963,000 SEK, with a gross profit of 232,427,000 SEK, suggesting high operating costs relative to revenue. The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification, which increases exposure to regional economic or regulatory risks. The lack of segmental or geographic breakdown in the financial data limits the ability to assess diversification benefits or concentration risks. Looking ahead, the company is expected to see a revenue increase to 345,000,000 SEK, a 21.96% year-over-year growth, according to analyst estimates. However, the operating cash flow of -31,930,000 SEK and free cash flow of -72,227,000 SEK indicate ongoing cash burn, which could constrain growth initiatives or necessitate external financing. The company faces liquidity and dilution risks, with a debt-to-equity ratio of 0.87 and a negative net cash position. Analysts have assigned a medium liquidity risk rating, and the company's dilution risk is currently low, with no near-term pressure expected. However, the negative operating cash flow and free cash flow suggest potential future dilution if the company requires additional capital. Recent financial filings and transcripts indicate that the company is in a development phase, with a focus on product innovation and market expansion. The company's current financial performance, including a net loss and negative cash flows, suggests that it is not yet generating sustainable profits and may require continued investment to achieve long-term growth.
Key takeaways
  • Magle Chemoswed Holding AB is trading at a significant discount to book value, with a price-to-book ratio of 0.27.
  • The company is unprofitable, with a return on equity of -40.39% and a net loss of 159,884,000 SEK.
  • Analysts expect a 21.96% year-over-year revenue increase to 345,000,000 SEK, but the company is currently burning cash.
  • The company has a negative net cash position and a debt-to-equity ratio of 0.87, indicating moderate leverage.
  • The company's revenue is concentrated in a single segment, with no geographic diversification disclosed.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencySEK
Revenue$282.9M
Gross profit$232.4M
Operating income-$127.0M
Net income-$159.9M
R&D
SG&A
D&A
SBC
Operating cash flow-$31.9M
CapEx-$12.6M
Free cash flow-$72.2M
Total assets$911.0M
Total liabilities$515.2M
Total equity$395.8M
Cash & equivalents$13.6M
Long-term debt$346.2M
Valuation
Market price$3.56
Market cap$105.0M
Enterprise value$437.6M
P/E
Reported non-GAAP P/E
EV/Revenue1.6
EV/Op income
EV/OCF
P/B0.3
P/Tangible book0.3
Tangible book$395.8M
Net cash-$332.6M
Current ratio1.4
Debt/Equity0.9
ROA-17.5%
ROE-40.4%
Cash conversion20.0%
CapEx/Revenue-4.5%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Pharmaceuticals · cohort 779 companies
MetricMAGLEActivity
Op margin-44.9%7.7% medp25 -2.4% · p75 15.5%bottom quartile
Net margin-56.5%5.9% medp25 -3.8% · p75 12.8%bottom quartile
Gross margin82.2%45.5% medp25 31.1% · p75 62.9%top quartile
R&D / revenue529.2% medp25 465.2% · p75 593.2%
CapEx / revenue-4.5%-7.0% medp25 -14.9% · p75 -3.2%above median
Debt / equity87.0%25.0% medp25 3.8% · p75 63.3%top quartile
Observations
IR observations
Mean price target25.00 SEK
Median price target25.00 SEK
High price target25.00 SEK
Low price target25.00 SEK
Mean EPS estimate1.40 SEK
Last actual EPS-7.74 SEK
Mean revenue estimate345,000,000 SEK
Last actual revenue282,920,000 SEK
Mean EBIT estimate37,000,000 SEK
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod financials
no public URL
2026-05-16 19:38 UTC#f80750f8
Source: analysis-pipeline (hybrid)Generated: 2026-05-28 11:58 UTCJob: 77b9e346